



Investor Webinar – Clinical Trial: Can PharmAust’s drug be the first effective treatment for motor neurone disease?

1 November 2022 – Perth, Australia: PharmAust Limited (ASX:PAA & PAAO) (“PharmAust” or “the Company”) invites shareholders and investors to a special webinar on the new clinical trial testing monepantel in patients living with motor neurone disease (MND).

When: 11:00am AEDT (8:00am AWST) 15 November 2022

Convenor: Michael Woods, Newburyport Partners

Speakers: Dr Sue Mathers, Calvary Health Care Bethlehem, Melbourne
Dr Rebecca Sheean, Research Director, FightMND

PharmAust recently announced the first four patients have been recruited and dosing with monepantel has commenced, with a number of additional patients currently undergoing screening. The trial is testing safety and tolerability and signs of slowing progression of MND.

The webinar will be hosted by Michael Woods, independent biotechnology investor. Principal Investigator Dr Sue Mathers will share her expertise on the disease and insight on monepantel and its unique potential to slow the progression of MND. Despite medical advancements, MND remains a terminal illness with no effective treatment or cure.

Dr Rebecca Sheean, Research Director of FightMND, will join the panel to share the story of FightMND’s search for a cure for MND, including its A\$881,085 investment in PharmAust’s monepantel trial.

To register:

https://us06web.zoom.us/webinar/register/WN_nf0sY2rdSsGshR3G-XvOVq

Webinar participants will be able to submit questions through Zoom chat during the presentation or are encouraged to submit questions beforehand via the registration page.

This ASX release has been approved for release by the Board of Directors.

Enquiries:

Anusha Aubert
Investor Relations

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com
T @PharmAust

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated \$3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

About FightMND:

Founded in 2014, FightMND was established in Australia with the purpose of finding effective treatments and ultimately a cure for Motor Neurone Disease (MND), also referred to as ALS or Lou Gehrig's Disease. FightMND, with its vision of a world without MND, is the largest independent funder of MND research in Australia. Since 2014, FightMND has investment more than \$63 million into MND research and care equipment to improve the lives of those fighting the disease. FightMND is determined to help facilitate the translation of the growing body of new knowledge about the disease into a cure for MND patients in Australia and abroad. For more information about FightMND, visit the website at <https://fightmnd.org.au>.